tiprankstipranks
Advertisement
Advertisement

CAPR Stock Latest News

Capricor Therapeutics Signs Strategic Headquarters Lease Agreement
Company AnnouncementsCapricor Therapeutics Signs Strategic Headquarters Lease Agreement
6d ago
8K
CAPR
Capricor Faces FDA Advisory Review for DMD Therapy
PremiumCompany Announcements
Capricor Faces FDA Advisory Review for DMD Therapy
24d ago
8K
CAPR
Midday Fly By: On Semi to acquire Synaptics, OpenAI leans toward 2027 IPO
PremiumThe Fly
Midday Fly By: On Semi to acquire Synaptics, OpenAI leans toward 2027 IPO
25d ago
BA
GS
Capricor announces FDA advisory committee meeting to review Deramiocel BLA
PremiumThe Fly
Capricor announces FDA advisory committee meeting to review Deramiocel BLA
25d ago
CAPR
Capricor presents five-year data from HOPE-2 open-label extension study
PremiumThe Fly
Capricor presents five-year data from HOPE-2 open-label extension study
25d ago
CAPR
Capricor Therapeutics management to meet with Oppenheimer
PremiumThe FlyCapricor Therapeutics management to meet with Oppenheimer
1M ago
CAPR
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot
Premium
Company Announcements
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot
2M ago
CAPR
CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CAPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CAPR
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy
PremiumCompany Announcements
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy
2M ago
CAPR
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
PremiumThe Fly
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
2M ago
CAPR
Analyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target
PremiumRatings
Analyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target
2M ago
CAPR
FDA Commissioner Marty Makary resigns
PremiumThe Fly
FDA Commissioner Marty Makary resigns
2M ago
AZN
BMY
Capricor Therapeutics options imply 9.4% move in share price post-earnings
PremiumThe FlyCapricor Therapeutics options imply 9.4% move in share price post-earnings
2M ago
CAPR
Capricor Buy Rating Reiterated on Deramiocel Opportunity and NS Pharma Dispute Dynamics; $50 Price Target Maintained
Premium
Ratings
Capricor Buy Rating Reiterated on Deramiocel Opportunity and NS Pharma Dispute Dynamics; $50 Price Target Maintained
2M ago
CAPR
Capricor files suit against NS Pharma over Deramiocel distribution deal
Premium
The Fly
Capricor files suit against NS Pharma over Deramiocel distribution deal
2M ago
CAPR
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
PremiumCompany Announcements
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
2M ago
8K
CAPR
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
PremiumMarket News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
4M ago
XEL
CAPR
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
PremiumThe Fly
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
4M ago
CAPR
Capricor Therapeutics Nears Key Milestones After Earnings Call
PremiumCompany Announcements
Capricor Therapeutics Nears Key Milestones After Earnings Call
4M ago
CAPR
Capricor selloff today a buying opportunity, says Roth Capital
PremiumThe FlyCapricor selloff today a buying opportunity, says Roth Capital
4M ago
CAPR
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
Premium
The Fly
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
4M ago
CAPR
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
Premium
The Fly
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
4M ago
CAPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >